April 23, 2026·4 min read·glp-1, metabolic, compound-overview
Semaglutide — a research overview
Mechanism, half-life, dose-response curve, and the human literature behind the most-studied GLP-1 receptor agonist of the last decade.
Mechanism, half-life, dose-response curve, and the human literature behind the most-studied GLP-1 receptor agonist of the last decade.
Semaglutide is the molecule that pulled GLP-1 receptor agonism from a niche diabetes therapy into one of the most-prescribed drug classes in modern medicine. Of the three commonly-discussed GLP-1 peptides — Semaglutide, Tirzepatide, Retatrutide — Semaglutide has the deepest human dataset, the longest post-marketing surveillance window, and the most stable dose-response characterization. If you're trying to understand the GLP-1 class, this is the right molecule to start with.
Semaglutide is a synthetic 31-amino-acid analogue of glucagon-like peptide-1, modified at two positions and conjugated to a fatty-acid side chain. The modifications matter for two reasons. First, position-8 substitution (alanine to alpha-aminoisobutyric acid) protects the molecule from DPP-4 cleavage, the enzyme that destroys native GLP-1 within minutes. Second, the C-18 fatty diacid linker drives reversible binding to serum albumin, which extends circulating half-life from minutes to roughly a week.
Once in circulation, Semaglutide binds the GLP-1 receptor on pancreatic beta cells (driving glucose-dependent insulin secretion), on the central nervous system (suppressing appetite via hypothalamic and brainstem pathways), and on gastric tissue (slowing gastric emptying). The appetite-suppressive mechanism — not the insulinotropic one — accounts for most of the body composition response in non-diabetic users.
Subcutaneous Semaglutide reaches peak plasma concentration at 1 to 3 days post-dose, with a terminal half-life of approximately 165 hours (around 7 days). This is the basis of the once-weekly dosing schedule. Steady-state concentrations are reached after 4 to 5 weeks of continuous dosing — a practical implication being that the user who quits at week 3 because "it's not working" hasn't yet tested the compound at therapeutic plasma levels.
Bioavailability after subcutaneous injection is approximately 89%. Site of injection (abdomen, thigh, upper arm) does not significantly affect absorption in the published comparisons.
The clinical literature has characterized the dose-response curve well. Starting doses of 0.25 mg weekly are titrated upward at four-week intervals to a maintenance range of 1.0 to 2.4 mg weekly, with the higher end driving the larger composition responses observed in the STEP trials. Above approximately 2.4 mg weekly, the curve flattens — incremental dose increases produce diminishing returns and increased GI side-effect burden.
The titration schedule is not optional. Starting at maintenance dose, rather than titrating, is the most reliable way to produce intolerable nausea and a discontinued cycle.
The STEP program (STEP 1 through STEP 8) is the largest body of randomized human evidence on Semaglutide for body composition. STEP 1 enrolled 1,961 adults without diabetes and reported a placebo-adjusted weight reduction of approximately 12.4% over 68 weeks at the 2.4 mg weekly dose. The SUSTAIN program covers diabetes endpoints with similar statistical depth, and the SELECT trial extended the dataset into cardiovascular outcome endpoints.
Cross-referencing across STEP, SUSTAIN, and SELECT, the magnitude and direction of effect are consistent. This is unusual for a peptide in 2026 — most of the catalog has nothing approaching this evidentiary base.
Run-in expectations. The first two to four weeks are the side-effect window — nausea, early satiety, occasional vomiting. These resolve as receptor adaptation occurs.
Lean-mass preservation. Composition trials show that 25 to 40% of total weight reduction on Semaglutide can come from lean mass without intervention. Concurrent resistance training and adequate protein intake (1.6+ g/kg) are the two interventions with the best published evidence for lean-mass preservation during the cycle. This principle is detailed in the GLP-1 receptor agonist comparison post.
Rebound. Discontinuation studies show partial weight regain over the year following cessation. Plan the off-cycle as deliberately as the on-cycle.
Semaglutide is the entry point into the GLP-1 category for users who want the deepest evidence base. Tirzepatide and Retatrutide (Retatrutide/009) sit on the same biological axis with broader receptor coverage and shallower human datasets — covered in the GLP-1 comparison post for users weighing across the class.
How long does it take semaglutide to reach steady state? Steady-state concentrations are reached after 4 to 5 weeks of continuous dosing at the same weekly dose. This is why early protocol discontinuation before week 3 or 4 often reflects sub-therapeutic plasma levels rather than true non-response.
What is the difference between semaglutide and tirzepatide? Semaglutide is a GLP-1 receptor agonist with 7+ years of post-marketing data. Tirzepatide is a dual GIP/GLP-1 agonist with a steeper dose-response curve and less data, but shows larger placebo-adjusted weight reduction in trials.
Why do people start semaglutide at 0.25 mg instead of the maintenance dose? The titration schedule minimizes gastrointestinal side effects (nausea, early satiety) that resolve as receptor adaptation occurs. Starting at maintenance dose (2.4 mg) produces intolerable nausea and typically leads to cycle discontinuation.
Can you preserve lean mass while on semaglutide? Composition trials show 25–40% of weight loss comes from lean mass without intervention. Concurrent resistance training and protein intake of 1.6+ g/kg are the evidence-backed interventions for lean-mass preservation.
What is the half-life of semaglutide? Subcutaneous semaglutide has a terminal half-life of approximately 165 hours (around 7 days), which is the basis for once-weekly dosing. Bioavailability after subcutaneous injection is approximately 89%.
